

PREFERRED PRACTICE PATTERN®

It is a committee developed by a panel of ophthalmologists with expertise in the guideline topic, a methodologist, and other experts.



Stephen D. McLeod, MD, Chair

Robert S. Feder, MD Timothy W. Olsen, MD Bruce E. Prum, Jr., MD C. Gail Summers, MD Ruth D.Williams, MD David C. Musch, PhD, MPH, Methodologist

Invited Reviewers

American Society of Retina Specialists Canadian Ophthalmological Society Central American Retina and Vitreous Society European Society of Retina Specialists The Macula Society National Eye Institute National Medical Association Pan-American Retina and Vitreous Society The Retina Society AMERICAN ACADEMY Thai Retina Society



PREFERRED PRACTICE PATTERN®

For each PPP, a detailed literature search of PubMed and the Cochrane Library for articles in the English language is conducted


The results are reviewed by an expert panel and used to prepare the recommendations, which are then given a rating that shows the <u>strength of evidence</u> when sufficient evidence exists.


PREFERRED PRACTICE PATTERN®

- > They provide guidance for practice not for the care of a particular individual.
- Preferred Practice Pattern[®] guidelines are not medical standards to be adhered to in all individual situations.

> They are reviewed annually and valid for 5 years.










ΟΤΤ	ISH INTERCOLLEGIATE GUIDELINE NETWORK (SIGN)
1++	 High quality meta-analyses, systematic reviews of RCTs RCTs with a very low risk of bias
1+	 Well-conducted meta-analyses, systematic reviews of RCTs RCTs with a low risk of bias
1-	 Meta-analyses, systematic reviews of RCTs RCTs with a high risk of bias
11 ++	 High-quality systematic reviews of case-control or cohort studies High-quality case-control or cohort studies with a very low risk of confounding or bias and high probability that the relationship is causal
H +	 Well-conducted case-control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal
H -	• Case-control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal.
ш	Case reports and case series.

RECOMMENDATIONS ASSESSMENT, GRADING OF **DEVELOPMENT AND EVALUATION (GRADE)** The body of evidence quality ratings are defined by GRADE as follows: Good quality (GQ) • Further research is very unlikely to change our confidence. Moderate quality • Further research is likely to have an important impact on our confidence in the estimate of the effect. (MQ) · Further research is very likely to have an important impact on our confidence in the Insufficient quality (IQ) estimate of effect • Estimate of effect is very uncertain.







HIGHLIGHTS AND RECOMMENDATIONS

Type I diabetes should have annual screenings for diabetic retinopathy beginning 5 years after the onset of their disease.

Type 2 diabetes should have a prompt examination at the time of diagnosis and at least yearly examinations thereafter. It's Good; Strong

Patients should be informed of the importance of maintaining good **AIC** levels, serum lipids, and blood pressure to lower the risk of retinopathy developing and/or progressing. I++; Good; Strong

Patients with diabetes may use aspirin for other medical indications. Herr Good; Discretionary

Gestational diabetes do not require an eye examination. However, diabetic pregnant women should be examined early in the course of the pregnancy. It'; Good; Strong

At this time, laser photocoagulation remains the preferred treatment for non-center-involving diabetic macular edema. Here Good, Strong

Disease Severity Level	Findings Observable upon Dilated Ophthalmoscopy			
No apparent retinopathy	No abnormalities			
Mild NPDR (see Glossary)	Microaneurysms only			
Moderate NPDR (see Glossary)	More than just microaneurysms but less than severe NPDR			
Severe NPDR				
U.S. Definition	Any of the following (4-2-1 rule) and no signs of proliferative retinopathy:			
	· Severe intraretinal hemorrhages and microaneurysms in each of four quadrants			
	 Definite venous beading in two or more quadrants 			
	 Moderate IRMA in one or more quadrants 			
International Definition	Any of the following and no signs of proliferative refinopathy:			
	 More than 20 intraretinal hemorrhages in each of four quadrants 			
	 Definite venous beading in two or more quadrants 			
	 Prominent IRMA in one or more quadrants 			
PDR	One or both of the following:			
	Neovascularization			
	 Vitreous/preretinal hemorrhage 			

RECOMMENDATIONS

TABLE 3	RECOMMENDED EVE E	XAMINATIONS FOR PATIEN	TS WITH DIABETES MELLIT	US AND NO DIABETIC	RETINOPATHY
---------	-------------------	------------------------	-------------------------	--------------------	-------------

Diabetes Type	Recommended Initial Evaluation	Recommended Follow-up*
Type 1	5 years after diagnosis™	Yearly ²⁹
Type 2	At time of diagnosis ^{13, 10}	Yearty ^{III, III}
Pregnancy! (Type 1 or Type 2)	Soon after conception and early in the first trimestor ^{is in}	 No retinopathy to mild or moderate NPDR: every 3–12 months⁵⁰⁻⁰¹
		 Severe NPDR or worse: every 1–3 months⁴³⁴⁶

Severity of Retinopath	y Presence of Macular Edema	Follow-up (Months)	Panretinal Photocoagulation (Scatter) Laser	Focal and/or Grid Laser*	Intravitreal Anti VEGF Therapy
Normal or minimal NPD	R No	12	No	No	No
Mid NPDR	No	12	No	No	No
	ME	4-6	No		
	CSMET	1*	No	Sometimes	Sometimes
Moderate NPDR	No	126	No	No	No
	ME	3-6	No		
	CSME?	1"	No	Sometimes	Sometimes
Severe NPOR Non-high-risk PDR High-risk PDR	 Neovascularization (a Neovascularization at Severe neovascularizi New vessels within quarter to one-thin 	tt any location) the optic disc ation: in one disc diam id disc area in si	wing four features cha eter of the optic nerve ze least one-half disc are	head that are larger	

The initial physical examination should include slit-lamp biomicroscopy: III; Good; Strong


The initial physical examination should include intraocular pressure: III; Good; Strong


The initial physical examination should include gonioscopy before dilation, when indicated: **III; Good; Strong**

POSSIBLE APPLICATION IN EGYPT

CARE PROCESS

It is recommended that an HbAlc of 7.0% or lower is the target for glycemic control in most patients while in selected patients, there may be some benefit to setting a target of 6.5%: I++; Good; Strong





SUMMARY

- **Preferred Practice Pattern**[®] is the highest level in the evidence pyramid.
- Preferred Practice Pattern[®] provide guidance for practice not for the care of a particular individual.
- Preferred Practice Pattern[®] guidelines are not medical standards to be adhered to in all individual situations.

